Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012
Ruopeng An,1 Peizhong Peter Wang,2 1Department of Kinesiology and Community Health, College of Applied Health Sciences, University of Illinois at Urbana-Champaign, Champaign, IL, USA; 2Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada Purpose: In this study,...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-01-01
|
Series: | Vascular Health and Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/length-of-stay-hospitalization-cost-and-in-hospital-mortality-in-us-ad-peer-reviewed-article-VHRM |
id |
doaj-7689f9744f46463eaefa668bd5cb9052 |
---|---|
record_format |
Article |
spelling |
doaj-7689f9744f46463eaefa668bd5cb90522020-11-25T01:38:23ZengDove Medical PressVascular Health and Risk Management1178-20482017-01-01Volume 13152130958Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012An RWang PPRuopeng An,1 Peizhong Peter Wang,2 1Department of Kinesiology and Community Health, College of Applied Health Sciences, University of Illinois at Urbana-Champaign, Champaign, IL, USA; 2Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada Purpose: In this study, we examined the length of stay, hospitalization cost, and risk of in-hospital mortality among US adult inpatients with immune thrombocytopenic purpura (ITP). Methods: We analyzed nationally representative data obtained from Nationwide/National Inpatient Sample database of discharges from 2006 to 2012. Results: In the US, there were an estimated 296,870 (95% confidence interval [CI]: 284,831–308,909) patient discharges recorded for ITP from 2006 to 2012, during which ITP-related hospitalizations had increased steadily by nearly 30%. The average length of stay for an ITP-related hospitalization was found to be 6.02 days (95% CI: 5.93–6.10), which is 28% higher than that of the overall US discharge population (4.70 days, 95% CI: 4.66–4.74). The average cost of ITP-related hospitalizations was found to be US$16,594 (95% CI: US$16,257–US$16,931), which is 48% higher than that of the overall US discharge population (US$11,200; 95% CI: US$11,033–US$11,368). Gender- and age-adjusted mortality risk in inpatients with ITP was 22% (95% CI: 19%–24%) higher than that of the overall US discharge population. Across diagnosis related groups, length of stay for ITP-related hospitalizations was longest for septicemia (7.97 days, 95% CI: 7.55–8.39) and splenectomy (7.40 days, 95% CI: 6.94–7.86). Splenectomy (US$25,262; 95% CI: US$24,044–US$26,481) and septicemia (US$18,430; 95% CI: US$17,353–US$19,507) were associated with the highest cost of hospitalization. The prevalence of mortality in ITP-related hospitalizations was highest for septicemia (11.11%, 95% CI: 9.60%–12.63%) and intracranial hemorrhage (9.71%, 95% CI: 7.65%–11.77%). Conclusion: Inpatients with ITP had longer hospital stay, bore higher costs, and faced greater risk of mortality than the overall US discharge population. Keywords: hospitalization, inpatient, cost, mortality, length of stay, immune thrombocytopenic purpura, national inpatient samplehttps://www.dovepress.com/length-of-stay-hospitalization-cost-and-in-hospital-mortality-in-us-ad-peer-reviewed-article-VHRMHospitalizationInpatientCostMortalityLength of stayImmune thrombocytopenic purpuraNational Inpatient Sample |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
An R Wang PP |
spellingShingle |
An R Wang PP Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012 Vascular Health and Risk Management Hospitalization Inpatient Cost Mortality Length of stay Immune thrombocytopenic purpura National Inpatient Sample |
author_facet |
An R Wang PP |
author_sort |
An R |
title |
Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012 |
title_short |
Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012 |
title_full |
Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012 |
title_fullStr |
Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012 |
title_full_unstemmed |
Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012 |
title_sort |
length of stay, hospitalization cost, and in-hospital mortality in us adult inpatients with immune thrombocytopenic purpura, 2006–2012 |
publisher |
Dove Medical Press |
series |
Vascular Health and Risk Management |
issn |
1178-2048 |
publishDate |
2017-01-01 |
description |
Ruopeng An,1 Peizhong Peter Wang,2 1Department of Kinesiology and Community Health, College of Applied Health Sciences, University of Illinois at Urbana-Champaign, Champaign, IL, USA; 2Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada Purpose: In this study, we examined the length of stay, hospitalization cost, and risk of in-hospital mortality among US adult inpatients with immune thrombocytopenic purpura (ITP). Methods: We analyzed nationally representative data obtained from Nationwide/National Inpatient Sample database of discharges from 2006 to 2012. Results: In the US, there were an estimated 296,870 (95% confidence interval [CI]: 284,831–308,909) patient discharges recorded for ITP from 2006 to 2012, during which ITP-related hospitalizations had increased steadily by nearly 30%. The average length of stay for an ITP-related hospitalization was found to be 6.02 days (95% CI: 5.93–6.10), which is 28% higher than that of the overall US discharge population (4.70 days, 95% CI: 4.66–4.74). The average cost of ITP-related hospitalizations was found to be US$16,594 (95% CI: US$16,257–US$16,931), which is 48% higher than that of the overall US discharge population (US$11,200; 95% CI: US$11,033–US$11,368). Gender- and age-adjusted mortality risk in inpatients with ITP was 22% (95% CI: 19%–24%) higher than that of the overall US discharge population. Across diagnosis related groups, length of stay for ITP-related hospitalizations was longest for septicemia (7.97 days, 95% CI: 7.55–8.39) and splenectomy (7.40 days, 95% CI: 6.94–7.86). Splenectomy (US$25,262; 95% CI: US$24,044–US$26,481) and septicemia (US$18,430; 95% CI: US$17,353–US$19,507) were associated with the highest cost of hospitalization. The prevalence of mortality in ITP-related hospitalizations was highest for septicemia (11.11%, 95% CI: 9.60%–12.63%) and intracranial hemorrhage (9.71%, 95% CI: 7.65%–11.77%). Conclusion: Inpatients with ITP had longer hospital stay, bore higher costs, and faced greater risk of mortality than the overall US discharge population. Keywords: hospitalization, inpatient, cost, mortality, length of stay, immune thrombocytopenic purpura, national inpatient sample |
topic |
Hospitalization Inpatient Cost Mortality Length of stay Immune thrombocytopenic purpura National Inpatient Sample |
url |
https://www.dovepress.com/length-of-stay-hospitalization-cost-and-in-hospital-mortality-in-us-ad-peer-reviewed-article-VHRM |
work_keys_str_mv |
AT anr lengthofstayhospitalizationcostandinhospitalmortalityinusadultinpatientswithimmunethrombocytopenicpurpura2006ndash2012 AT wangpp lengthofstayhospitalizationcostandinhospitalmortalityinusadultinpatientswithimmunethrombocytopenicpurpura2006ndash2012 |
_version_ |
1725054146727378944 |